Neonatal Disruption of Serine Racemase Causes Schizophrenia-Like Behavioral Abnormalities in Adulthood: Clinical Rescue by D-Serine

被引:27
作者
Hagiwara, Hiroko [1 ,2 ]
Iyo, Masaomi [2 ]
Hashimoto, Kenji [1 ]
机构
[1] Chiba Univ, Ctr Forens Mental Hlth, Div Clin Neurosci, Chiba, Japan
[2] Chiba Univ, Grad Sch Med, Dept Psychiat, Chiba, Japan
关键词
AMINO-ACID OXIDASE; INDUCED COGNITIVE DEFICITS; PREPULSE INHIBITION DEFICITS; RAT-BRAIN; NEGATIVE SYMPTOMS; CEREBROSPINAL-FLUID; MODULATORY SITE; HIGH-RISK; GENE G72; NMDA;
D O I
10.1371/journal.pone.0062438
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: D-Serine, an endogenous co-agonist of the N-methyl-D-aspartate (NMDA) receptor, is synthesized from L-serine by serine racemase (SRR). Given the role of D-serine in both neurodevelopment and the pathophysiology of schizophrenia, we examined whether neonatal disruption of D-serine synthesis by SRR inhibition could induce behavioral abnormalities relevant to schizophrenia, in later life. Methodology/Principal Findings: Neonatal mice (7-9 days) were injected with vehicle or phenazine methosulfate (Met-Phen: 3 mg/kg/day), an SRR inhibitor. Behavioral evaluations, such as spontaneous locomotion, novel object recognition test (NORT), and prepulse inhibition (PPI) were performed at juvenile (5-6 weeks old) and adult (10-12 weeks old) stages. In addition, we tested the effects of D-serine on PPI deficits in adult mice after neonatal Met-Phen exposure. Finally, we assessed whether D-serine could prevent the onset of schizophrenia-like behavior in these mice. Neonatal Met-Phen treatment reduced D-serine levels in the brain, 24 hours after the final dose. Additionally, this treatment caused behavioral abnormalities relevant to prodromal symptoms in juveniles and to schizophrenia in adults. A single dose of D-serine improved PPI deficits in adult mice. Interestingly, chronic administration of D-serine (900 mg/kg/day from P35 to P70) significantly prevented the onset of PPI deficits after neonatal Met-Phen exposure. Conclusions/Significance: This study shows that disruption of D-serine synthesis during developmental stages leads to behavioral abnormalities relevant to prodromal symptoms and schizophrenia, in later life. Furthermore, early pharmacological intervention with D-serine may prevent the onset of psychosis in adult.
引用
收藏
页数:8
相关论文
共 69 条
[1]   Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior [J].
Basu, A. C. ;
Tsai, G. E. ;
Ma, C-L ;
Ehmsen, J. T. ;
Mustafa, A. K. ;
Han, L. ;
Jiang, Z. I. ;
Benneyworth, M. A. ;
Froimowitz, M. P. ;
Lange, N. ;
Snyder, S. H. ;
Bergeron, R. ;
Coyle, J. T. .
MOLECULAR PSYCHIATRY, 2009, 14 (07) :719-727
[2]   A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia [J].
Bendikov, Inna ;
Nadri, Carmit ;
Amar, Shirly ;
Panizzutti, Rogerio ;
De Miranda, Joari ;
Wolosker, Herman ;
Agam, Galila .
SCHIZOPHRENIA RESEARCH, 2007, 90 (1-3) :41-51
[3]  
BRAFF DL, 1990, ARCH GEN PSYCHIAT, V47, P181
[4]   Plasma levels of D-serine in Brazilian individuals with schizophrenia [J].
Calcia, Marilia A. ;
Madeira, Caroline ;
Alheira, Flavio V. ;
Silva, Thuany C. S. ;
Tannos, Filippe M. ;
Vargas-Lopes, Charles ;
Goldenstein, Nelson ;
Brasil, Marco Antonio ;
Ferreira, Sergio T. ;
Panizzutti, Rogerio .
SCHIZOPHRENIA RESEARCH, 2012, 142 (1-3) :83-87
[5]   Impact of Neurocognition on Social and Role Functioning in Individuals at Clinical High Risk for Psychosis [J].
Carrion, Ricardo E. ;
Goldberg, Terry E. ;
McLaughlin, Danielle ;
Auther, Andrea M. ;
Correll, Christoph U. ;
Cornblatt, Barbara A. .
AMERICAN JOURNAL OF PSYCHIATRY, 2011, 168 (08) :806-813
[6]   Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia [J].
Chumakov, I ;
Blumenfeld, M ;
Guerassimenko, O ;
Cavarec, L ;
Palicio, M ;
Abderrahim, H ;
Bougueleret, L ;
Barry, C ;
Tanaka, H ;
La Rosa, P ;
Puech, A ;
Tahri, N ;
Cohen-Akenine, A ;
Delabrosse, S ;
Lissarrague, S ;
Picard, FP ;
Maurice, K ;
Essioux, L ;
Millasseau, P ;
Grel, P ;
Debailleul, V ;
Simon, AM ;
Caterina, D ;
Dufaure, I ;
Malekzadeh, K ;
Belova, M ;
Luan, JJ ;
Bouillot, M ;
Sambucy, JL ;
Primas, G ;
Saumier, M ;
Boubkiri, N ;
Martin-Saumier, S ;
Nasroune, M ;
Peixoto, H ;
Delaye, A ;
Pinchot, V ;
Bastucci, M ;
Guillou, S ;
Chevillon, M ;
Sainz-Fuertes, R ;
Meguenni, S ;
Aurich-Costa, J ;
Cherif, D ;
Gimalac, A ;
Van Duijn, C ;
Gauvreau, D ;
Quelette, G ;
Fortier, I ;
Realson, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) :13675-13680
[7]   The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia [J].
Coyle, JT ;
Tsai, G .
PSYCHOPHARMACOLOGY, 2004, 174 (01) :32-38
[8]   G72/G30 in schizophrenia and bipolar disorder: Review and meta-analysis [J].
Detera-Wadleigh, Sevilla D. ;
McMahon, Francis J. .
BIOLOGICAL PSYCHIATRY, 2006, 60 (02) :106-114
[9]   Redox dysregulation, neurodevelopment, and schizophrenia [J].
Do, Kim Q. ;
Cabungcal, Jan H. ;
Frank, Anita ;
Steullet, Pascal ;
Cuenod, Michel .
CURRENT OPINION IN NEUROBIOLOGY, 2009, 19 (02) :220-230
[10]  
Ferraris DV, 2011, CURR PHARM DESIGN, V17, P103